Abstract: The invention relates to R-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazinone of formula (1), and to S-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazinone of formula (2), and to acid-addition salts thereof as well as pharmaceutical compositions containing these compounds. Furthermore, the invention relates to a process for the preparation of the above compounds. The new starting compounds of formulae (4) and (5) are also involved in the scope of the invention. The compounds according to the invention possess &agr;1- and &agr;2-adrenoceptor antagonistic effects and urogenital selectivity. Thus, they are useful for the treatment of the benign prostate hyperplasia.

Abstract: The invention relates to new 4-aryl-2-methyl-1,2,3,4-tetrahydro-isoquinoline derivatives of the general Formula I ##STR1## and salts thereof whereinR stands for hydrogen, lower alkyl or halogen andX represents a group of the general Formula --(CH.sub.2).sub.n --NR.sup.1 R.sup.2, --NH--R.sup.3 or --OR.sup.4, in whichR.sup.1 and R.sup.2 may be the same or different and stand for hydrogen or lower alkyl or R.sup.1 and R.sup.2 together with the adjacent nitrogen atom, they are attached to, form a 5- or 6-membered saturated heterocyclic ring which may optionally contain a further oxygen or sulfur atom or an optionally lower alkyl substituted imino group;n is an integral number 1, 2, 3 or 4;R.sup.3 stands for lower alkyl or optionally substituted phenyl andR.sup.4 is lower alkyl, halogeno lower alkyl, or phenyl lower alkyl.The compounds of the general Formula I are useful as antidepressants and antiparkinsone agents.The compounds of the general Formula I can be prepared by methods known per se.